Clinical Trial Update: Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating dabrafenib plus trametinib in advanced solid tumors with BRAF V600E mutation or actionable BRAF alterations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Se Jun Park | Conditions: Cancer | Phase 2 | Status: UNKNOWN